PHRI :: Barry Kreiswirth, Ph.D.

   Yuri Bushkin, Ph.D.
   Loren Day, Ph.D.
   Karl Drlica, Ph.D.
   David Dubnau, Ph.D.
   Marila Gennaro, M.D.
   Gilla Kaplan, Ph.D.
   Fred Kramer, Ph.D.
   Barry Kreiswirth, Ph.D.
   Leonard Mindich, Ph.D.
   Harvey Penefsky, Ph.D.
   David Perlin, Ph.D.
   Richard Pine, Ph.D.
   Abraham Pinter, Ph.D.
   Issar Smith, Ph.D.
   Patricia Soteropoulos, Ph.D.
   Sanjay Tyagi, Ph.D.
   David Wah, Ph.D.
   Shuishu Wang, Ph.D.

   Research Faculty
   Xilin Zhao, Ph.D.

Barry Kreiswirth, Ph.D.
	Recent Articles Shopsin B, Zhao X, Kreiswirth BN, Tillotson GS, Drlica K. (2004). *Are the new quinolones appropriate treatment for community-acquired methicillin-resistant Staphylococcus aureus?* Int J Antimicrob Agents. 2004 Jul;24(1):32-4 PMID: 15225857 The use of quinolones in the treatment of non-serious community-acquired methicillin-resistant Staphylococcus aureus is discussed. The new C8-modified quinolones may be suitable for such treatment but controlled trials should be carried out to ensure that the pharmacokinetics are such that there is little risk of resistance developing.

Copyright © 2008 All rights reserved.